| Sora Pediatric Therapy | |
|
1891 Station Pkwy Nw, Andover, MN 55304 | |
| (763) 755-4275 | |
| (763) 755-4261 |
| Full Name | Sora Pediatric Therapy |
|---|---|
| Type | Facility |
| Speciality | Speech-language Pathologist |
| Location | 1891 Station Pkwy Nw, Andover, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235285966 | NPI | - | NPPES |
| 01043879 | Other | MN | PREFERRED ONE |
| 150165800 | Medicaid | MN | |
| 73G75FA | Other | MN | BLUE CROSS BLUE SHIELD |
| 99915 | Other | MN | HEALTHPARTNERS |
| Provider Name | Kristin L Connell |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1336244375 PECOS PAC ID: 7113923434 Enrollment ID: I20061010000529 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Pamela S Lundequam |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1063598605 PECOS PAC ID: 8527068238 Enrollment ID: I20070103000219 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Katherine I Wacker |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1720285638 PECOS PAC ID: 3971699745 Enrollment ID: I20071010000341 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Andria Marie Davis |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487043865 PECOS PAC ID: 2567789522 Enrollment ID: I20150331002902 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Melissa S Lonsky |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1013063213 PECOS PAC ID: 0446577720 Enrollment ID: I20150417000906 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Emily J Jung |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1447532494 PECOS PAC ID: 4183938509 Enrollment ID: I20150729009552 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Molly M Nordberg |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1508275207 PECOS PAC ID: 5597079913 Enrollment ID: I20150729009704 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Alicia J Marten |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1841414794 PECOS PAC ID: 4981918208 Enrollment ID: I20150730013539 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kelly L Hungaski |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1235357898 PECOS PAC ID: 9234273863 Enrollment ID: I20150730013822 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Sarah S Biers |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1154313161 PECOS PAC ID: 1355655507 Enrollment ID: I20150731014785 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Carrie L Jerylo |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1770629297 PECOS PAC ID: 9830404961 Enrollment ID: I20150818004918 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Jessica L Naiberg |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1215208939 PECOS PAC ID: 9032410006 Enrollment ID: I20151216000876 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Sarah N Zinkel |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1437335643 PECOS PAC ID: 7416258942 Enrollment ID: I20151229000262 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Jennifer A Schwalbach |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932463379 PECOS PAC ID: 3971805052 Enrollment ID: I20160106001615 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kristine S Vogtlin |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1558816470 PECOS PAC ID: 9032406525 Enrollment ID: I20160927002347 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Laura M Bollig |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1144778044 PECOS PAC ID: 7012298540 Enrollment ID: I20161221001176 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Leeann Rae Kyriakides |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1285681247 PECOS PAC ID: 0143503946 Enrollment ID: I20170201001092 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Deborah L Gabel |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164949178 PECOS PAC ID: 9537435680 Enrollment ID: I20171018000823 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kathryn E Perovich |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1871012815 PECOS PAC ID: 1355617333 Enrollment ID: I20171018001913 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Saige Baker-lietz |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417460809 PECOS PAC ID: 8022376490 Enrollment ID: I20171213002464 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Sara Jesse Gleason |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1457871956 PECOS PAC ID: 5597023721 Enrollment ID: I20171218001079 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Anne Catherine Mugaas |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1982103289 PECOS PAC ID: 7012279748 Enrollment ID: I20180316001886 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Courtney Lyn Sanocki |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1497299499 PECOS PAC ID: 6608130596 Enrollment ID: I20180430002422 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kaylin Horne |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1134631682 PECOS PAC ID: 9638428584 Enrollment ID: I20180827000046 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Ellen Johnson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1073096608 PECOS PAC ID: 9234481375 Enrollment ID: I20181017003177 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Maria Faye Davis |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760984181 PECOS PAC ID: 3173875242 Enrollment ID: I20181018000502 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kerri Mulder |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1245718535 PECOS PAC ID: 1850645177 Enrollment ID: I20181126001261 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Bryden Giving |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1144794413 PECOS PAC ID: 0648510693 Enrollment ID: I20190329000111 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Nicole Rechtzigel |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1558921064 PECOS PAC ID: 8022340413 Enrollment ID: I20191105000923 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Michelle A Deremer |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1326697756 PECOS PAC ID: 5395177919 Enrollment ID: I20191119002365 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Laura L Jaeger |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1326684556 PECOS PAC ID: 7810321965 Enrollment ID: I20191223001720 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Raina Demarais |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1700416914 PECOS PAC ID: 3173953684 Enrollment ID: I20200424001332 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Lindsey Hove |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932732179 PECOS PAC ID: 0749610194 Enrollment ID: I20200427000000 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Alissa Deardorff |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1528693785 PECOS PAC ID: 4082045745 Enrollment ID: I20200513000027 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Jaidyn Johnson |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1376178442 PECOS PAC ID: 8022449750 Enrollment ID: I20200513003241 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Amy Brisson |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1235741604 PECOS PAC ID: 3870910102 Enrollment ID: I20200901000524 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Alexi Mercedes Leclaire |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1679129795 PECOS PAC ID: 9638400534 Enrollment ID: I20200901000931 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Stephanie Frey |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1992353882 PECOS PAC ID: 8729405972 Enrollment ID: I20200902001008 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Elsie Mcclelland |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1518592625 PECOS PAC ID: 6507285947 Enrollment ID: I20201002002715 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Andrea Christ |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1780285072 PECOS PAC ID: 9739592395 Enrollment ID: I20201229001121 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Lindsey Koosman |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1710535604 PECOS PAC ID: 0941614523 Enrollment ID: I20210121001814 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Paige Melby |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417550898 PECOS PAC ID: 3678988342 Enrollment ID: I20210211001123 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Shelly Sontag-johnson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164018263 PECOS PAC ID: 5193130391 Enrollment ID: I20210222001577 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Victoria Shear |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1710589023 PECOS PAC ID: 2466867304 Enrollment ID: I20210226000971 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Abby Rose Kargul |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427679992 PECOS PAC ID: 4385050335 Enrollment ID: I20210317000784 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Taylor M Grootwassink |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1811572936 PECOS PAC ID: 5890103972 Enrollment ID: I20210412000225 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Ellen Stowe |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1205411428 PECOS PAC ID: 0840609541 Enrollment ID: I20210510002514 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Melody Koerselman |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1346828548 PECOS PAC ID: 8426467135 Enrollment ID: I20210511000266 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Mariel Leigh Goettsch |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1902158132 PECOS PAC ID: 8325457963 Enrollment ID: I20210511001540 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Brittany Wickoren |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1215515424 PECOS PAC ID: 0042619280 Enrollment ID: I20210520001622 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kathryn Rubinchik |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1669734638 PECOS PAC ID: 1759689805 Enrollment ID: I20210707000905 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Alyssa Besch |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1972117463 PECOS PAC ID: 7911301718 Enrollment ID: I20210802000388 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Andrea Zeng |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1386216711 PECOS PAC ID: 0244634830 Enrollment ID: I20210804000701 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Natalie J Frier |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1205397726 PECOS PAC ID: 6507260890 Enrollment ID: I20210809002906 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Nicole Marie Chisholm |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1013592542 PECOS PAC ID: 2961810510 Enrollment ID: I20210809003052 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Courtney Wagner |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1023680451 PECOS PAC ID: 3870997018 Enrollment ID: I20210810001294 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kimberlee B Gross |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1164701074 PECOS PAC ID: 6002212842 Enrollment ID: I20210902002189 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Roxana Isabel Chirinos |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1366119638 PECOS PAC ID: 4789081951 Enrollment ID: I20210930002371 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Molly O'donnell Nicolai |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1609206119 PECOS PAC ID: 2668860636 Enrollment ID: I20211025000265 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Ashely Ka Zoua Xiong |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487318572 PECOS PAC ID: 9234527847 Enrollment ID: I20211102000285 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Sydney M Brock |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1508354325 PECOS PAC ID: 2668863259 Enrollment ID: I20211215000364 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Carlene Osweiler |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1558027284 PECOS PAC ID: 4082006085 Enrollment ID: I20220125002889 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Sarah Sneltjes |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770249401 PECOS PAC ID: 5991198210 Enrollment ID: I20220209002762 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Morgan Evitts |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1669138384 PECOS PAC ID: 8628462587 Enrollment ID: I20220218002169 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Madecyn Caroline Franz |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1700495587 PECOS PAC ID: 9335534098 Enrollment ID: I20220315001867 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Jennifer Anne Jordan |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1851617575 PECOS PAC ID: 3577959568 Enrollment ID: I20220330002285 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Evelyn L Mueggenberg |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1649913468 PECOS PAC ID: 6709264104 Enrollment ID: I20220525001505 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Lucy M Zeihen |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770226441 PECOS PAC ID: 7012395411 Enrollment ID: I20220525001674 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Amber Bauer |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1255097986 PECOS PAC ID: 5597143909 Enrollment ID: I20220525001974 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kendra Mertes |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1750033593 PECOS PAC ID: 8224416516 Enrollment ID: I20220526002643 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Morgan Marie Voss |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699224923 PECOS PAC ID: 0941688238 Enrollment ID: I20220526002672 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kiley Hogg |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1245723105 PECOS PAC ID: 7911385208 Enrollment ID: I20220526002761 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Autumn Dose |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1356074140 PECOS PAC ID: 8729463310 Enrollment ID: I20220919000510 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Molly Pybas |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1578296372 PECOS PAC ID: 8921483546 Enrollment ID: I20220919001765 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Emelia Miner |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1548988900 PECOS PAC ID: 9335524966 Enrollment ID: I20220919002082 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Taylor Freese |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1497488209 PECOS PAC ID: 2860877495 Enrollment ID: I20220919002192 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Allyson Hansen Rogers |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1649903444 PECOS PAC ID: 4688059215 Enrollment ID: I20220919002198 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kallie Medenwald |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1649903451 PECOS PAC ID: 2668857194 Enrollment ID: I20220919002665 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kaley Rae Anderson |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1780233536 PECOS PAC ID: 8729463252 Enrollment ID: I20220919002739 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Stephanie Olson |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1568195360 PECOS PAC ID: 7810372364 Enrollment ID: I20220919003250 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Hannah Smoker |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1972221331 PECOS PAC ID: 8527443076 Enrollment ID: I20220919003292 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Sydney Lenz |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1699493056 PECOS PAC ID: 5890170344 Enrollment ID: I20220919003334 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Jessica Blum |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1326766783 PECOS PAC ID: 2062897549 Enrollment ID: I20220920001190 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Sara Dasler |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1518685973 PECOS PAC ID: 9335524834 Enrollment ID: I20220920002162 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Grace Bestler |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1437877891 PECOS PAC ID: 2567847080 Enrollment ID: I20220920002906 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Ashley Stephens |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1700519519 PECOS PAC ID: 6507242948 Enrollment ID: I20221007001794 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Callie Aho |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1376266197 PECOS PAC ID: 2668841230 Enrollment ID: I20221205000912 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Cassandra Wald |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1801225685 PECOS PAC ID: 0749650349 Enrollment ID: I20221222001789 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Alyssa Smith |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1881239143 PECOS PAC ID: 4183094790 Enrollment ID: I20221222001949 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kristina Dose |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1033834775 PECOS PAC ID: 5890165419 Enrollment ID: I20221222002504 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Maria Miller |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1437865052 PECOS PAC ID: 0648644229 Enrollment ID: I20230322000701 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Suzanne Berg |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1124723416 PECOS PAC ID: 2466817614 Enrollment ID: I20230424001197 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Caitlyn Bath |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1629770144 PECOS PAC ID: 4880059484 Enrollment ID: I20230504001023 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Holly Shilling |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1952001208 PECOS PAC ID: 4082070214 Enrollment ID: I20230515000782 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Claire Oberle |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1306405428 PECOS PAC ID: 5193181212 Enrollment ID: I20230516001878 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Jacqueline Jeziorski |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1386362747 PECOS PAC ID: 8628434594 Enrollment ID: I20230518001891 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Sadie George |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1629768874 PECOS PAC ID: 4284090879 Enrollment ID: I20230524002701 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Hailey Nelson |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1801529607 PECOS PAC ID: 6002272549 Enrollment ID: I20230525001323 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Montana Nelson |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1306537899 PECOS PAC ID: 4284093675 Enrollment ID: I20230703001176 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Hannah Arason |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1669157202 PECOS PAC ID: 5092174896 Enrollment ID: I20230711001549 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Brittany Erickson |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1174217459 PECOS PAC ID: 7911366729 Enrollment ID: I20230711001803 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Michelle Macgillivray |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1346926755 PECOS PAC ID: 6800255647 Enrollment ID: I20230711002708 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Megan Dierking |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1003591652 PECOS PAC ID: 7315307097 Enrollment ID: I20230712003985 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Jordan Enevold |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1851076202 PECOS PAC ID: 4981064565 Enrollment ID: I20230713003240 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Haley Lipscomb |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487248019 PECOS PAC ID: 6406216035 Enrollment ID: I20230714000804 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Lydia Nemeth |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1740973080 PECOS PAC ID: 6002277993 Enrollment ID: I20230725000954 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Madeline Wells |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1497449979 PECOS PAC ID: 7113388935 Enrollment ID: I20230726002401 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Ashley Sprain |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1073292322 PECOS PAC ID: 9931560463 Enrollment ID: I20230801001382 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Loran Hawkins |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1245918515 PECOS PAC ID: 9133580327 Enrollment ID: I20230803004026 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Morgan Heilman |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1508543315 PECOS PAC ID: 4789047754 Enrollment ID: I20230824001836 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Alison O'sadnick |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1225774060 PECOS PAC ID: 6002279486 Enrollment ID: I20230901000494 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Madeline Clubb |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1447944749 PECOS PAC ID: 1254795149 Enrollment ID: I20230911003407 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Inga Rohde |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1144908930 PECOS PAC ID: 2365806296 Enrollment ID: I20230912000753 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Laura Marie Jakes |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1730841081 PECOS PAC ID: 4486008117 Enrollment ID: I20230928001202 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Andrea Konz |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1609653344 PECOS PAC ID: 8224482971 Enrollment ID: I20230928001895 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Sarah Mcgoldrick |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770267916 PECOS PAC ID: 2668829581 Enrollment ID: I20231114001198 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Kristine Girbe |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932972445 PECOS PAC ID: 6204286826 Enrollment ID: I20231222001097 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Ellison Rose Schmillen |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1912775982 PECOS PAC ID: 0042660094 Enrollment ID: I20240103001876 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Provider Name | Rachel Evavold |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1689444234 PECOS PAC ID: 4880047661 Enrollment ID: I20240129000951 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sora Pediatric Therapy 1891 Station Pkwy Nw, Andover, MN 55304 Ph: (763) 755-4275 | Sora Pediatric Therapy 1891 Station Pkwy Nw, Andover, MN 55304 Ph: (763) 755-4275 |
News Archive
The NIH Nanotechnology Task Force and the NIH Nanomedicine Roadmap Initiative will host NanoWeek 2009 from Tuesday, April 7 through Friday, April 10 at the Natcher Conference Center on the NIH campus in Bethesda, Md. NIH's first-of-a-kind series of events focusing on science at the nanoscale, NanoWeek 2009 will include symposia with experts in the field, demonstrations, talks, and posters from NIH scientists.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
Susannah Briskin, MD, a pediatric sports medicine specialist with University Hospitals Rainbow Babies & Children's Hospital, is the co-author of an updated report from the American Academy of Pediatrics (AAP) strongly cautioning against home trampolines. The report provides updated data on the number of and types of injuries caused by trampolines.
› Verified 2 days ago
Megan Dierking, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1891 Station Pkwy Nw, Andover, MN 55304 Phone: 763-755-4275 | |
Mrs. Melissa Sue Lonsky, CCC-SLP, OM Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 13750 Crosstown Dr Nw, Andover, MN 55304 Phone: 763-755-4275 Fax: 763-755-4261 | |
Courtney Wagner, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1891 Station Pkwy Nw, Andover, MN 55304 Phone: 763-755-4275 | |
Kristina Dose, MA, SLLP-CF/DE Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1891 Station Pkwy Nw, Andover, MN 55304 Phone: 763-755-4275 Fax: 763-755-4261 | |
Ms. Kelsey Anne Wegner, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1891 Station Pkwy Nw, Andover, MN 55304 Phone: 763-755-4275 | |
Nicole Morrissey, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1891 Station Pkwy Nw, Andover, MN 55304 Phone: 763-350-0371 | |
Kayla Braun, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1891 Station Pkwy Nw, Andover, MN 55304 Phone: 763-755-4275 |